Kayser, VayselTarkistani, Mariam2023-12-122023-12-122023-12-09https://hdl.handle.net/20.500.14154/70185Cancer is one of the most significant global public health issues. During the past several decades, substantial efforts have been undertaken to fight cancer. Traditional cancer treatments involve chemotherapy, surgery, and radiotherapy. However, these treatments are quite invasive and have varying success rates and adverse effects. Thus, more innovative strategies are required to treat cancer. Targeted drug delivery is among the most promising innovative strategies. Every tumour has overexpressed special receptors; hence, delivery of a specifically targeted drug to those receptors can induce tumour regression. Drug delivery to the tumour can be achieved using nanoparticles. However, bioavailability could still be poor even with targeted drug delivery and when administered directly into the bloodstream. The bioavailability of nanomaterials can be improved greatly when delivered using a T-cell engager nanoparticles-based carrier system. The aim of this thesis is to develop a next generation nanoparticle (NPs) based on immunotherapy T-cell engager. The NP complex will activate and recruit immune cells to cancer site in order to facilitate their killing effect. The new platform described in this thesis could potentially be used for a variety of solid cancer types. We thoroughly characterised our bispecifics and evaluated their cytotoxic capacity. Based on cytotoxic tests, our bispecifics are excellent drug candidates for various types of cancer. This idea paves the way to target two mechanisms. The mechanisms include recognising and targeting cancer cells and activating T-cells to induce an immune response involving T-cell proliferation and cytokine production, which leads to the elimination of cancer cells. These concepts are further discussed in subsequent chapters of this thesis.202enNanohybridNanoparticleCancerTargeted DeliveryIron NPsGold NPsThesis